Kura Oncology (KURA)
(Delayed Data from NSDQ)
$21.76 USD
-0.30 (-1.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $21.79 +0.03 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 101 - 120 ( 258 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Previewing a Busy Q4: ASH Data Potential for Differentiation
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 101122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 10122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 92122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 91122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Time to Step Up for These Catalysts; Making Real Differences
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 9122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 82122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 81122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Ziftomenib's Top-Line Data Likely Key Driver at ASH''22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Zifotemenib RP2D Identified; Data Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 8122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 72122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 71122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 7122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 62122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 61122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for KURA 6122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for KURA.
Provider: Stock Traders Daily
Analyst: Research Department